Ninety percent of prostatitis cases are of unknown cause, and these data are the first to implicate antiandrogenic EDCs as a causative factor in the etiology of this inflammatory disease of the prostate via activation of the classical NFκB inflammatory pathway. The gene discussed is NFKB1; the disease is male reproductive organ cancer.